{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:56:43Z","timestamp":1775473003030,"version":"3.50.1"},"reference-count":23,"publisher":"Medical Association of Zenica-Doboj","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicinski Glasnik"],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:p>&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Aim&amp;lt;br \/&amp;gt;&amp;lt;\/strong&amp;gt; To investigate the effects of carbocisteine treatment in the reduction of frequency of productive cough episodes, preventing disease progression and improving the quality of life as well as the tolerability of the administered treatment and patient compliance during the study. &amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Methods&amp;lt;br \/&amp;gt;&amp;lt;\/strong&amp;gt; This observational, non-interventional, multicenter, cohort study included 501 patients with chronic obstructive pulmonary disease (COPD) who were administrated carbocisteine capsules 375 mg and followed up during the next 15 days. The patients were observed at 3 points, baseline and two additional assessments. General clinical condition of patients, along with the spirometry testing at all three points were examined. Thr quality of life was assessed on the 1st and 3rd observation with Leicester Cough Questionnaire. Tolerability and patient compliance were measured throughout the study. &amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Results&amp;lt;br \/&amp;gt;&amp;lt;\/strong&amp;gt; There was a significant change of forced expiratory volume in 1 second (FEV1) status between the second and third observation (p=0.002). Examination of general symptoms showed a statistically significant reduction in cough by 74.9%, in sputum production by 48.5%, in dyspnea by 29% and in fatigue by 50%. After the administration of carbocisteine the median value of overall quality of life was 3.79 (3.63-3.89). &amp;lt;br \/&amp;gt;&amp;lt;strong&amp;gt;Conclusion&amp;lt;br \/&amp;gt;&amp;lt;\/strong&amp;gt;375mg carbocisteine capsules were found to be effective and well-tolerated in the treatment of COPD, with a small percentage of reported mild adverse reactions and with a significant improvement of quality of life.&amp;lt;\/p&amp;gt;<\/jats:p>","DOI":"10.17392\/906-17","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:20:46Z","timestamp":1713694846000},"page":"182-188","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of carbocisteine in the treatment of chronic obstructive pulmonary disease and impact on the quality of life"],"prefix":"10.17392","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5779-0769","authenticated-orcid":false,"given":"Esad","family":"Aliba\u0161i\u0107","sequence":"first","affiliation":[{"name":"Primary Health Care Center Kalesija","place":["Kalesija,Bosnia and Herzegovina"],"department":["Department of Family Medicine"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira","family":"Skopljak","sequence":"additional","affiliation":[{"name":"Health Care Centre of Canton Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"\u010cengi\u0107","sequence":"additional","affiliation":[{"name":"Health Care Centre of Canton Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorana","family":"Krstovi\u0107","sequence":"additional","affiliation":[{"name":"Health Care Centre of Canton Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nata\u0161a","family":"Trifunovi\u0107","sequence":"additional","affiliation":[{"name":"Health Care Centre of Canton Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarik","family":"\u010cati\u0107","sequence":"additional","affiliation":[{"name":"\u2018\u2019Bosnalijek\u2019\u2019 d.d., Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belma","family":"Kapo","sequence":"additional","affiliation":[{"name":"\u2018\u2019Bosnalijek\u2019\u2019 d.d., Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meliha","family":"Mehi\u0107","sequence":"additional","affiliation":[{"name":"\u2018\u2019Bosnalijek\u2019\u2019 d.d., Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amila","family":"Had\u017eimuratovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Sarajevo","place":["Sarajevo,Bosnia and Herzegovina"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"49509","published-online":{"date-parts":[[2017,8,1]]},"reference":[{"key":"ref1","first-page":"982","article-title":"Epidemiology of chronic obstructive pulmonary disease","author":"JAnt\u00f3J","year":"2001","unstructured":"Ant\u00f3 JM, Vermeire P, Vestbo J, Sunyer J. Epidemio-\nlogy of chronic obstructive pulmonary disease. Eur \nResp J 2001; 17:982-94.","journal-title":"Eur Resp J"},{"key":"ref2","article-title":"Chronic obstructive pulmonary disease","author":"VVijayanV","unstructured":"Vijayan VK. Chronic obstructive pulmonary disea-\nse."},{"key":"ref3","first-page":"251","year":"2013","unstructured":"Indian J Med Res 2013; 137:251-69.","journal-title":"Indian J Med Res"},{"key":"ref4","article-title":"Health statistics annual Federation of Bosnia and Herzegovina","year":"2014. 2014","unstructured":"Institute of Public health of Federation of Bosnia and \nHerzegovina. Health statistics annual Federation of \nBosnia and Herzegovina 2014. Sarajevo: Maligraf, \n2014."},{"key":"ref5","first-page":"457","article-title":"Epidemiology of chronic obstructive pulmonary disease: a literature review","author":"CRycroftC","year":"2012","unstructured":"Rycroft C, Heyes A, Lanza L, and Becker E. Epide-\nmiology of chronic obstructive pulmonary disease: \na literature review. Int J Chron Obstruct Pulmon Dis \n2012; 7:457-94.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref6","first-page":"213","article-title":"Epidemiology of COPD","author":"CRaherisonC","year":"2009","unstructured":"Raherison C, Girodet PO. Epidemiology of COPD. \nEur Respir Rev 2009; 18:213-21.","journal-title":"Eur Respir Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1183\/13993003.01170-2015","article-title":"A review of national guidelines for management of COPD in Europe","author":"MMiravitllesM","year":"2016","unstructured":"Miravitlles M, Vogelmeier C, Roche N, Halpin D, \nCardoso J, Chuchalin AG, Kankaanranta H, San-\ndstr\u00f6m T, \u015aliwi\u0144ski P, Zatloukal J, Blasi F. A review \nof national guidelines for management of COPD in \nEurope. Eur Respir J 2016; 47:625-37.","journal-title":"Eur Respir J"},{"key":"ref8","first-page":"1884","article-title":"Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease","author":"KTatsumiK","year":"2007","unstructured":"Tatsumi K, Fukuchi Y. Carbocisteine improves qu-\nality of life in patients with chronic obstructive pul-\nmonary disease. J Am Geriatr Soc 2007; 55:1884-6.","journal-title":"J Am Geriatr Soc"},{"key":"ref9","first-page":"5","article-title":"Translation and adaptation of Leichester Cough Questionnaire (LCQ) for use in Bosnia and Herzegovina as quality of life measure instrument in acute and chronic cough","author":"T\u010cati\u0107T","year":"2016","unstructured":"\u010cati\u0107 T, Kapo B, Duranovi\u0107 LR, Krstovi\u0107 G, Mehi\u0107 \nM. Translation and adaptation of Leichester Cough \nQuestionnaire (LCQ) for use in Bosnia and Herze-\ngovina as quality of life measure instrument in acute \nand chronic cough. Pharmacia 2016; 19:5-10.","journal-title":"Pharmacia"},{"key":"ref10","first-page":"134","article-title":"Mucoactive therapy in COPD","author":"MDecramerM","year":"2010","unstructured":"Decramer M, Janssens W. Mucoactive therapy in \nCOPD. Eur Respir Rev 2010; 19:134-40.","journal-title":"Eur Respir Rev"},{"key":"ref11","first-page":"127","article-title":"Mucoactive drugs","author":"RBalsamoR","year":"2010","unstructured":"Balsamo R, Lanata L, Egan CG. Mucoactive drugs. \nEur Respir Rev 2010; 19:127-33.","journal-title":"Eur Respir Rev"},{"key":"ref12","first-page":"659","article-title":"The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease","author":"CHooperC","year":"2008","unstructured":"Hooper C, Calvert J. The role for S-car-\nboxymethylcysteine (carbocisteine) in the manage-\nment of chronic obstructive pulmonary disease. Int J \nChron Obstruct Pulmon Dis 2008; 3:659-69.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref13","first-page":"1418","article-title":"Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease","author":"TarSeemungalTar","year":"1998","unstructured":"Seemungal TAR, Donaldson GC, Paul EA, Bestall \nJC, Jeffries DJ, Wedzicha JA. Effect of Exacerbation \non Quality of Life in Patients with Chronic Obstruc-\ntive Pulmonary Disease. Am J Respir Crit Care Med \n1998; 157:1418-22.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","first-page":"1657","article-title":"Impact of chronic cough on quality of life","author":"CFrenchC","year":"1998","unstructured":"French CL, Irwin RS, Curley FJ, Krikorian CJ. Im-\npact of chronic cough on quality of life. Arch Intern \nMed 1998; 158:1657-61.","journal-title":"Arch Intern Med"},{"key":"ref15","first-page":"2013","article-title":"Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomized placebo-controlled study","author":"JZhengJ","year":"2008","unstructured":"Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, \nYang L, Bai CX, Wang CZ, Wang C, Chen BY, Shi \nY, Liu CT, Chen P, Li Q, Wang ZS, Huang YJ, Luo \nZY, Chen FP, Yuan JZ, Yuan BT, Qian HP, Zhi RC, \nZhong NS. Effect of carbocisteine on acute exacer-\nbations of chronic obstructive pulmonary disease \n(PEACE study): a randomized placebo-controlled \nstudy. Lancet 2008; 371:2013-8.","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review","author":"PPooleP","year":"2001","unstructured":"Poole PJ, Black PN. Oral mucolytic drugs for exa-\ncerbations of chronic obstructive pulmonary disease: \nsystematic review. BMJ 2001; 322:1271.","journal-title":"BMJ"},{"key":"ref17","first-page":"1123","article-title":"Evaluation of a cough-specific quality-of-life questionnaire","author":"CFrenchC","year":"2002","unstructured":"French CT, Irwin RS, Fletcher KE, Adams TM. \nEvaluation of a cough-specific quality-of-life questi-\nonnaire. Chest 2002; 121:1123-31.","journal-title":"Chest"},{"key":"ref18","article-title":"Efikasnost karbocistina u tretmanu hroni\u010dne opstruktivne plu\u0107ne bolesti i njegov utjecaj na kvalitet \u017eivota","unstructured":"Efikasnost karbocistina u tretmanu hroni\u010dne opstruktivne plu\u0107ne \nbolesti i njegov utjecaj na kvalitet \u017eivota"},{"key":"ref19","article-title":"Esad Aliba\u0161i\u0107 1 , Amira Skopljak 2 , Aida \u010cengi\u0107 2 , Gorana Krstovi\u0107 2 , Nata\u0161a Trifunovi\u0107 2 , Tarik \u010cati\u0107 3","unstructured":"Esad Aliba\u0161i\u0107 1 , Amira Skopljak 2 , Aida \u010cengi\u0107 2 , Gorana Krstovi\u0107 2 , Nata\u0161a Trifunovi\u0107 2 , Tarik \u010cati\u0107 3 , Belma \nKapo 3 , Meliha Mehi\u0107 3 , Amila Had\u017eimuratovi\u0107 4","journal-title":"Amila Had\u017eimuratovi\u0107"},{"key":"ref20","article-title":"Centar za porodi\u010dnu medicinu, Dom zdravlja Kalesija, Kalesija, 2 Dom zdravlja Kantona Sarajevo, Sarajevo, 3 Bosnalijek d.d., Sarajevo, 4 Medicinski fakultet Univerziteta u Sarajevu, Sarajevo SA\u017dETAK Cilj Ispitati efekte terapije s karbocisteinom u smanjenju u\u010destalosti epizoda produktivnog ka\u0161lja, spre\u010davanju progresije bolesti i pobolj\u0161anju kvalitete \u017eivota","unstructured":"1 Centar za porodi\u010dnu medicinu, Dom zdravlja Kalesija, Kalesija, 2 Dom zdravlja Kantona Sarajevo, Sarajevo, 3 Bosnalijek d.d., Sarajevo, \n4 Medicinski fakultet Univerziteta u Sarajevu, Sarajevo \nSA\u017dETAK \nCilj Ispitati efekte terapije s karbocisteinom u smanjenju u\u010destalosti epizoda produktivnog ka\u0161lja, spre-\n\u010davanju progresije bolesti i pobolj\u0161anju kvalitete \u017eivota, te podno\u0161ljivost primijenjene terapije i surad-\nljivost ispitanika tokom istra\u017eivanja."},{"key":"ref21","article-title":"Metode Ova opservacijska, neintervencijska, multicentri\u010dna, kohortna studija uklju\u010divala je 501 pacijenta s hroni\u010dnom opstruktivnom plu\u0107nom bolesti (HOPB), kojima su ordinirane kapsule karbocisteina od 375 mg, te su pra\u0107eni narednih 15 dana. Pacijenti su se pratili kroz tri mjerenja: nulto i dva kontrolna. Op\u0107e klini\u010dko stanje i spirometrija su pra\u0107eni tokom sva tri mjerenja. Kvalitet \u017eivota je procjenjivan na prvom i tre\u0107em mjerenju, koriste\u0107i Leicester Cough Questionnaire","unstructured":"Metode Ova opservacijska, neintervencijska, multicentri\u010dna, kohortna studija uklju\u010divala je 501 paci-\njenta s hroni\u010dnom opstruktivnom plu\u0107nom bolesti (HOPB), kojima su ordinirane kapsule karbocisteina \nod 375 mg, te su pra\u0107eni narednih 15 dana. Pacijenti su se pratili kroz tri mjerenja: nulto i dva kontrolna. \nOp\u0107e klini\u010dko stanje i spirometrija su pra\u0107eni tokom sva tri mjerenja. Kvalitet \u017eivota je procjenjivan na \nprvom i tre\u0107em mjerenju, koriste\u0107i Leicester Cough Questionnaire. Podno\u0161ljivost terapije i suradljivost \nispitanika su pra\u0107eni tokom \u010ditave studije."},{"key":"ref22","article-title":"Ispitivanje op\u0107ih simptoma pokazalo je statisti\u010dki zna\u010dajno smanjenje ka\u0161lja za 74.9%, iska\u0161ljaja za 48.5%, dispneje za 29% i zamora za 50%. Nakon terapije karbocisteinom srednja vrijednost kvalitete \u017eivota","unstructured":"Rezultati Postojala je zna\u010dajna promjena FEV1 statusa izme\u0111u drugog i tre\u0107eg mjerenja (p=0.002). \nIspitivanje op\u0107ih simptoma pokazalo je statisti\u010dki zna\u010dajno smanjenje ka\u0161lja za 74.9%, iska\u0161ljaja za \n48.5%, dispneje za 29% i zamora za 50%. Nakon terapije karbocisteinom srednja vrijednost kvalitete \n\u017eivota iznosila je 3.79 (3.63 -3.89)."},{"key":"ref23","article-title":"Zaklju\u010dak Primjena karbocistein kapsula od 375 mg pokazala se efikasnom, i dobro podno\u0161ljivom u tretmanu HOPB-a, sa rijetkim ne\u017eeljenim efektima te zna\u010dajnim pobolj\u0161anjem kvalitete \u017eivota pacijenata","unstructured":"Zaklju\u010dak Primjena karbocistein kapsula od 375 mg pokazala se efikasnom, i dobro podno\u0161ljivom u \ntretmanu HOPB-a, sa rijetkim ne\u017eeljenim efektima te zna\u010dajnim pobolj\u0161anjem kvalitete \u017eivota pacijenata. \nKlju\u010dne rije\u010di: plu\u0107ne bolesti, ka\u0161alj, ekspektoranti"}],"container-title":["Medicinski Glasnik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medicinskiglasnik.ba\/article\/47\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicinskiglasnik.ba\/article\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:43:39Z","timestamp":1775468619000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicinskiglasnik.ba\/article\/id\/89\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,8,1]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.17392\/906-17","archive":["Internet Archive"],"relation":{"is-cited-by":[{"id-type":"doi","id":"10.1186\/s13063-020-04701-8","asserted-by":"object"}]},"ISSN":["1840-0132","1840-0132"],"issn-type":[{"value":"1840-0132","type":"electronic"},{"value":"1840-0132","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}